Genscript Biotech Stock Buy Hold or Sell Recommendation
| GNNSF Stock | USD 1.37 0.01 0.72% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Genscript Biotech is 'Strong Sell'. Macroaxis provides Genscript Biotech buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GNNSF positions.
Check out Genscript Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Genscript and provide practical buy, sell, or hold advice based on investors' constraints. Genscript Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Genscript |
Execute Genscript Biotech Buy or Sell Advice
The Genscript recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Genscript Biotech. Macroaxis does not own or have any residual interests in Genscript Biotech or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Genscript Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Genscript Biotech Trading Alerts and Improvement Suggestions
| Genscript Biotech generated a negative expected return over the last 90 days | |
| Genscript Biotech may become a speculative penny stock | |
| The company reported the revenue of 510.6 M. Net Loss for the year was (347.87 M) with profit before overhead, payroll, taxes, and interest of 303.48 M. | |
| Genscript Biotech has accumulated about 1.26 B in cash with (136.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 38.0% of the company shares are held by company insiders |
Genscript Biotech Returns Distribution Density
The distribution of Genscript Biotech's historical returns is an attempt to chart the uncertainty of Genscript Biotech's future price movements. The chart of the probability distribution of Genscript Biotech daily returns describes the distribution of returns around its average expected value. We use Genscript Biotech price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Genscript Biotech returns is essential to provide solid investment advice for Genscript Biotech.
| Mean Return | -0.22 | Value At Risk | -0.72 | Potential Upside | 0.00 | Standard Deviation | 2.10 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Genscript Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Genscript Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Genscript Biotech or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Genscript Biotech's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Genscript pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.2 | |
β | Beta against Dow Jones | -0.3 | |
σ | Overall volatility | 2.02 | |
Ir | Information ratio | -0.17 |
Genscript Biotech Volatility Alert
Genscript Biotech exhibits very low volatility with skewness of -3.07 and kurtosis of 18.53. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Genscript Biotech's pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Genscript Biotech's pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Genscript Biotech Fundamentals Vs Peers
Comparing Genscript Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Genscript Biotech's direct or indirect competition across all of the common fundamentals between Genscript Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Genscript Biotech or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Genscript Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Genscript Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Genscript Biotech to competition |
| Fundamentals | Genscript Biotech | Peer Average |
| Return On Equity | -0.56 | -0.31 |
| Return On Asset | -0.12 | -0.14 |
| Profit Margin | (0.66) % | (1.27) % |
| Operating Margin | (0.64) % | (5.51) % |
| Current Valuation | 5.11 B | 16.62 B |
| Shares Outstanding | 2.12 B | 571.82 M |
| Shares Owned By Insiders | 38.31 % | 10.09 % |
| Shares Owned By Institutions | 24.68 % | 39.21 % |
| Price To Earning | 200.00 X | 28.72 X |
| Price To Book | 6.65 X | 9.51 X |
| Price To Sales | 10.82 X | 11.42 X |
| Revenue | 510.6 M | 9.43 B |
| Gross Profit | 303.48 M | 27.38 B |
| EBITDA | (494 M) | 3.9 B |
| Net Income | (347.87 M) | 570.98 M |
| Cash And Equivalents | 1.26 B | 2.7 B |
| Cash Per Share | 0.60 X | 5.01 X |
| Total Debt | 121.07 M | 5.32 B |
| Debt To Equity | 0.56 % | 48.70 % |
| Current Ratio | 2.92 X | 2.16 X |
| Book Value Per Share | 0.36 X | 1.93 K |
| Cash Flow From Operations | (136.79 M) | 971.22 M |
| Earnings Per Share | (0.17) X | 3.12 X |
| Number Of Employees | 5.57 K | 18.84 K |
| Beta | 1.35 | -0.15 |
| Market Capitalization | 6.67 B | 19.03 B |
| Total Asset | 2.23 B | 29.47 B |
| Z Score | 33.0 | 8.72 |
| Net Asset | 2.23 B |
Genscript Biotech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Genscript . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 1.37 | |||
| Day Typical Price | 1.37 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) |
About Genscript Biotech Buy or Sell Advice
When is the right time to buy or sell Genscript Biotech? Buying financial instruments such as Genscript Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Genscript Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Thematic Idea Now
Obamacare
Health care services and providers including hospitals, clinics and nursing homes that hope to benefit from Obamacare program. The Obamacare theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Genscript Pink Sheet
Genscript Biotech financial ratios help investors to determine whether Genscript Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.